Adverse Drug Reactions Resulting From the Use of Chiral Medicines Amoxicillin, Amoxicillin-Clavulanic Acid, and Ceftriaxone: A Mixed Prospective-Retrospective Cohort Study
Open Access
- 1 January 2024
- journal article
- research article
- Published by SAGE Publications in INQUIRY: The Journal of Health Care Organization, Provision, and Financing
- Vol. 61
Abstract
The use of chiral medicines (possessing center(s) of asymmetric carbon) may cause adverse drug reactions (ADRs). The safety assurance of these medicines is critical. We aimed to evaluate registered and commonly used anti-infective chiral medicines circulating in the Tanzanian market to establish their safety profile to protect public health. A mixed prospective-retrospective cohort study was conducted to assess the safety profile of amoxicillin, amoxicillin-clavulanic acid and ceftriaxone injection. ADRs causality assessment was conducted by using World Health Organization (WHO)-Algorithm criteria. Data were collected from 7 tertiary hospitals: Muhimbili National Hospital (MNH), Kilimanjaro Christian Medical Centre (KCMC), Bugando Medical Centre (BMC), Ligula Referral-Regional Hospital (LRRH), Kitete Referral-Regional Hospital (KRRH), Dodoma Referral-Regional Hospital (DRRH), and Mbeya Zonal-Referral Hospital (MZRH). Data were supplemented by those recorded in the WHO-Vigiflow/VigiLyze database within the same monitoring period. Data were analyzed using STATA version-15. The results were considered statistically significant when P < .05. A total of 2522 patients were enrolled in hospitals: MNH (499), KCMC (407), BMC (396), LRRH (387), KRRH (345), DRRH (249), and MZRH (239). Among those, 1197 (47.5%) were treated with ceftriaxone, 585 (23.2%) amoxicillin and 740(29.3%) amoxicillin-clavulanic acid. Out of those, 102 (4.5%) experienced adverse events (AEs), 49 (48%) were due to ceftriaxone, 37 (36.3%) amoxicillin-clavulanic acid and 16 (15.7%) amoxicillin ( P-value .012). A total of 443 participants from the enrolled and WHO-Vigiflow/VigiLyze database were experienced with ADRs. The ADRs affected mainly gastro-intestinal system 234 (53%), skin and subcutaneous tissue 85 (19%), nervous system 49 (11%), respiratory thoracic 22 (5%), and general disorders 18(4%). In this study, approximately 90% of reported AEs were ADRs possible-related to the monitored medicines, with few plausible and certain. Ceftriaxone injection caused more ADRs. Amoxicillin-clavulanic acid was associated with more ADRs than amoxicillin alone. The safety profile of these medicines is still maintained; however, comprehensive monitoring of ADRs is recommended to improve patient safety and enhance overall treatment outcomes.Keywords
Funding Information
- European and Developing Countries Clinical Trials Partnership (CSA2016ERC-1432 - SMERT Project)
- European and Developing Countries Clinical Trials Partnership (CSA2019ERC-2683 - ASCEND Project)
- Tanzania Medicines and Medical Devices Authority
This publication has 43 references indexed in Scilit:
- Association of Adverse Events With Antibiotic Use in Hospitalized PatientsJAMA Internal Medicine, 2017
- The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC studyBMC Family Practice, 2016
- Preclinical rodent toxicity studies for long term use of ceftriaxoneToxicology Reports, 2015
- Eslicarbazepine acetate: An update on efficacy and safety in epilepsyEpilepsy Research, 2014
- Fatal adverse effects of injected ceftriaxone sodium in ChinaPharmacoepidemiology and Drug Safety, 2012
- Adverse events induced by ceftriaxone: a 10-year review of reported cases to Iranian Pharmacovigilance CentreJournal of Clinical Pharmacy and Therapeutics, 2011
- Amoxicillin and amoxicillin plus clavulanate: a safety reviewExpert Opinion on Drug Safety, 2008
- Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in ItalyJournal of Antimicrobial Chemotherapy, 2007
- Do Women Have More Adverse Drug Reactions?American Journal of Clinical Dermatology, 2001
- Efficacy and safety of ceftriaxone in serious pediatric infectionsAntimicrobial Agents and Chemotherapy, 1983